Enoximone: Difference between revisions

Jump to navigation Jump to search
WikiBot (talk | contribs)
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)
Alonso Alvarado (talk | contribs)
No edit summary
Line 40: Line 40:
[[Category:Phosphodiesterase inhibitors]]
[[Category:Phosphodiesterase inhibitors]]
[[Category:Thioethers]]
[[Category:Thioethers]]
[[Category:Cardiovascular drugs]]
[[Category:Drugs]]
[[Category:Drugs]]



Revision as of 19:16, 24 July 2014

Enoximone
Clinical data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability50% (oral)
Protein binding85%
MetabolismHepatic oxidation
Elimination half-life4 to 10 hours
ExcretionRenal (60 to 70%)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H12N2O2S
Molar mass248.302 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.


Template:Phosphodiesterase inhibitors Template:Cardiac stimulants excluding cardiac glycosides

uk:Еноксімон


Template:WikiDoc Sources